News from ICER: November 2019
- 3 Downloads
The US Institute for Clinical and Economic Review (ICER) has finalised adaptations to its value assessment framework for assessments of potential cures and other treatments considered high-impact single or short-term therapies (SSTs).1
The finalisation of the adaptations follows a year-long period of collaboration with the UK National Institute for Health and Care Excellence (NICE) and the Canadian Agency for Drugs and Technologies in Health (CADTH). The adaptations will be launched by ICER in 2020 as part of an overall update to the value assessment framework.
Key adaptations of ICER's methods include: additional specific optimistic and conservative scenarios for assessing the benefits of SSTs; new dimensions of benefits and contextual considerations for voting by independent appraisal committees on potential other benefits and disadvantages; and two additional scenarios for assessing the potential impact that sharing savings of downstream cost offsets between society and the...
- 1.Institute for Clinical and Economic Review. ICER Finalizes Method Adaptations for Assessing Potential Cures and Other High-Impact Single or Short-term Therapies. Internet Document : 12 Nov 2019. Available from: URL: https://icer-review.org/announcements/final_potential_cures_methods/
- 2.Institute for Clinical and Economic Review. ICER Seeks Public Input to Guide Selection of Non-Drug Assessment Topics for 2020. Internet Document : 13 Nov 2019. Available from: URL: https://icer-review.org/announcements/potential_2020_non-drug_topics/
- 3.Institute for Clinical and Economic Review. ICER Releases Evidence Report on JAK Inhibitors to Treat Rheumatoid Arthritis. Internet Document : 26 Nov 2019. Available from: URL: https://icer-review.org/announcements/jak_inhibitor_evidence_report/